All In Biotech

Drug Trial Radar · NCT03539536

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer

Last checked: Nov 20, 2026Latest source record: Nov 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

270

Actual

Start

Oct 10, 2018

Primary completion

Jul 2026

Study completion Aug 2026

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
May 29, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that overexpress c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand the group(s) to further evaluate efficacy in the selected population(s) (Stage 2). After the Stage 2 global enrollment is completed, an additional cohort at an alternate dose level will evaluate the safety and efficacy of telisotuzumab vedotin (Stage 3).

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • Telisotuzumab vedotinDrug

    Intravenous (IV) infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (ORR) (Stage 1 and Stage 2)Time frame: Up to approximately 3 years
  2. Number of Participants with Adverse Events (Alternate dose cohort)Time frame: Up to approximately 3 years

Locations

252 sites in 26 countries. Site status is shown where the registry gives one.

  • University of South Alabama /ID# 212939

    Mobile, Alabama

  • Mayo Clinic Arizona /ID# 218550

    Phoenix, Arizona

  • Highlands Oncology Group, PA /ID# 215600

    Springdale, Arkansas

  • University of California, Los Angeles /ID# 203219

    Los Angeles, California

  • LA Hematology-Oncology Med Group /ID# 203338

    Orange, California

  • Sutter Medical Center Sacramen /ID# 203299

    Sacramento, California

  • Icri /Id# 227835

    Whittier, California

  • Univ of Colorado Cancer Center /ID# 203212

    Aurora, Colorado

  • Duplicate_Rocky Mountain Cancer Centers - Lone Tree /ID# 215789

    Lone Tree, Colorado

  • Advanced Cancer Treatment Center /ID# 239565

    Brooksville, Florida

  • AdventHealth Celebration /ID# 215649

    Celebration, Florida

  • Duplicate_Mayo Clinic /ID# 218488

    Jacksonville, Florida

  • Duplicate_AdventHealth Cancer Institute - Orlando /ID# 239960

    Orlando, Florida

  • Straub Clinic and Hospital /ID# 217905

    Honolulu, Hawaii

  • Northwestern University Feinberg School of Medicine /ID# 203239

    Chicago, Illinois

  • The University of Chicago Medical Center /ID# 203216

    Chicago, Illinois

  • Duplicate_NorthShore University HealthSystem /ID# 215583

    Evanston, Illinois

  • Ingalls Memorial Hosp /ID# 203228

    Harvey, Illinois

  • Joliet Oncology-Hematology Associates, LTD /ID# 203238

    Joliet, Illinois

  • Goshen Center for Cancer Care /ID# 215584

    Goshen, Indiana

  • Univ Kansas Med Ctr /ID# 216804

    Kansas City, Kansas

  • Cancer Center of Kansas /ID# 203235

    Wichita, Kansas

  • Duplicate_Baptist Health /ID# 203283

    Lexington, Kentucky

  • Duplicate_Norton Cancer Institute - St Matthews /ID# 203284

    Louisville, Kentucky

  • Central Maine Medical Center /ID# 216583

    Lewiston, Maine

  • Massachusetts General Hospital /ID# 203215

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center /ID# 208124

    Boston, Massachusetts

  • Dana-Farber Cancer Institute /ID# 203248

    Boston, Massachusetts

  • Henry Ford Hospital /ID# 203220

    Detroit, Michigan

  • Mayo Clinic - Rochester /ID# 215603

    Rochester, Minnesota

  • Hattiesburg Clinic /ID# 227691

    Hattiesburg, Mississippi

  • St. Lukes Cancer Institute /ID# 227697

    Kansas City, Missouri

  • Washington University-School of Medicine /ID# 203217

    St Louis, Missouri

  • Duplicate_Intermountain Health - St Vincent Regional Hospital - Cancer Centers o /ID# 203292

    Billings, Montana

  • Duplicate_Dartmouth-Hitchcock Medical Center - 1 Medical Center Drive /ID# 203350

    Lebanon, New Hampshire

  • Titan Health Partners LLC, d/b/a Astera Cancer Care /ID# 228868

    East Brunswick, New Jersey

  • Atlantic Health System /ID# 203404

    Morristown, New Jersey

  • Capital Health Medical Center /ID# 203403

    Pennington, New Jersey

  • Overlook Medical Center /ID# 211160

    Summit, New Jersey

  • University of New Mexico /ID# 208339

    Albuquerque, New Mexico

Showing 40 of 252 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.